Becton Dickinson Operating Income 2010-2024 | BDX
Becton Dickinson annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Becton Dickinson operating income for the quarter ending September 30, 2024 was $0.650B, a 85.19% increase year-over-year.
- Becton Dickinson operating income for the twelve months ending September 30, 2024 was $2.424B, a 14.83% increase year-over-year.
- Becton Dickinson annual operating income for 2024 was $2.426B, a 14.92% increase from 2023.
- Becton Dickinson annual operating income for 2023 was $2.111B, a 7.53% decline from 2022.
- Becton Dickinson annual operating income for 2022 was $2.283B, a 1.42% increase from 2021.
Becton Dickinson Annual Operating Income
(Millions of US $) |
| 2024 |
$2,426 |
| 2023 |
$2,111 |
| 2022 |
$2,283 |
| 2021 |
$2,251 |
| 2020 |
$912 |
| 2019 |
$1,760 |
| 2018 |
$1,509 |
| 2017 |
$1,522 |
| 2016 |
$1,430 |
| 2015 |
$1,074 |
| 2014 |
$1,606 |
| 2013 |
$1,255 |
| 2012 |
$1,558 |
| 2011 |
$1,665 |
| 2010 |
$1,582 |
| 2009 |
$1,590 |
Becton Dickinson Quarterly Operating Income
(Millions of US $) |
| 2024-09-30 |
$650 |
| 2024-06-30 |
$602 |
| 2024-03-31 |
$734 |
| 2023-12-31 |
$438 |
| 2023-09-30 |
$351 |
| 2023-06-30 |
$547 |
| 2023-03-31 |
$627 |
| 2022-12-31 |
$586 |
| 2022-09-30 |
$489 |
| 2022-06-30 |
$537 |
| 2022-03-31 |
$566 |
| 2021-12-31 |
$691 |
| 2021-09-30 |
$84 |
| 2021-06-30 |
$492 |
| 2021-03-31 |
$433 |
| 2020-12-31 |
$1,242 |
| 2020-09-30 |
$-317 |
| 2020-06-30 |
$359 |
| 2020-03-31 |
$369 |
| 2019-12-31 |
$501 |
| 2019-09-30 |
$112 |
| 2019-06-30 |
$626 |
| 2019-03-31 |
$136 |
| 2018-12-31 |
$886 |
| 2018-09-30 |
$576 |
| 2018-06-30 |
$511 |
| 2018-03-31 |
$187 |
| 2017-12-31 |
$235 |
| 2017-09-30 |
$491 |
| 2017-06-30 |
$-224 |
| 2017-03-31 |
$445 |
| 2016-12-31 |
$810 |
| 2016-09-30 |
$97 |
| 2016-06-30 |
$516 |
| 2016-03-31 |
$465 |
| 2015-12-31 |
$352 |
| 2015-09-30 |
$295 |
| 2015-06-30 |
$137 |
| 2015-03-31 |
$293 |
| 2014-12-31 |
$349 |
| 2014-09-30 |
$401 |
| 2014-06-30 |
$446 |
| 2014-03-31 |
$381 |
| 2013-12-31 |
$378 |
| 2013-09-30 |
$77 |
| 2013-06-30 |
$405 |
| 2013-03-31 |
$381 |
| 2012-12-31 |
$392 |
| 2012-09-30 |
$389 |
| 2012-06-30 |
$449 |
| 2012-03-31 |
$383 |
| 2011-12-31 |
$337 |
| 2011-09-30 |
$364 |
| 2011-06-30 |
$447 |
| 2011-03-31 |
$440 |
| 2010-12-31 |
$413 |
| 2010-09-30 |
$316 |
| 2010-06-30 |
$423 |
| 2010-03-31 |
$414 |
| 2009-12-31 |
$430 |
| 2009-09-30 |
$379 |
| 2009-06-30 |
$432 |
| 2009-03-31 |
$361 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$64.352B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
